3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
48
Prostatic Neoplasms, Castration-Resistant
3
Adenocarcinoma
3
Urogenital Neoplasms
2
Salivary Gland Neoplasms
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Neoplasm Metastasis
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Male Urogenital Diseases
2
Bulbo-Spinal Atrophy, X-Linked
2
Biochemically Recurrent Prostate Cancer
2
Urogenital Diseases
1
Triple Negative Breast Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Genital Diseases, Male
1
Fatigue
1
Depression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
Methotrexate
6
Cyclophosphamide
6
ponatinib
5
Cytarabine
5
merphos
4
Mycophenolic Acid
4
blinatumomab
3
Whole-Body Irradiation
3
Tacrolimus
3
Peripheral Blood Stem Cell Transplantation
3
Cyclosporine
3
venetoclax
2
fludarabine phosphate
2
bosutinib
2
Vincristine
2
Rituximab
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Idarubicin
2
Etoposide
2
Cladribine
2
CT-P10
2
Busulfan
2
prednylidene
1
pegfilgrastim
1
nilotinib
1
midostaurin
1
gilteritinib
1
fludarabine
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Blast Crisis
×
darolutamide
×
1 year
×
Clear all
No trials found.